Online citations, reference lists, and bibliographies.
← Back to Search

Cerebral Glucose Metabolism In Patients With AD And Different APOE Genotypes

A. Drzezga, M. Riemenschneider, B. Strassner, T. Grimmer, M. Peller, A. Knoll, S. Wagenpfeil, S. Minoshima, M. Schwaiger, A. Kurz
Published 2005 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Objective: To examine the influence of the APOE ε4 allele on cerebral glucose metabolism in a large series of patients with Alzheimer disease (AD). Methods: Eighty-three patients (41 APOE ε4 positive and 42 ε4 negative) were selected from a pre-existing databank of patients with AD (n > 1,000). The patients were carefully matched for age, age at onset, approximate disease duration, educational level, and overall degree of cognitive impairment. Cerebral [18F]fluorodeoxyglucose PET imaging was performed in all patients by a standardized protocol. Statistical comparison of patient PET data vs a healthy control population was performed as well as an analysis of differences between groups (SPM99; Wellcome Department of Cognitive Imaging, London, UK). Results: A similar pattern of cerebral hypometabolism was detected in the ε4-positive and -negative patient groups vs healthy volunteers in regions typically affected by AD (bilateral temporal, parietal, posterior cingulate, and prefrontal cortical areas). The comparison between ε4-positive and -negative patients additionally revealed stronger abnormalities in ε4 carriers in parietal, temporal, and posterior cingulate cortical regions. Conclusions: A generally similar pattern of cerebral hypometabolism was detected in APOE ε4-positive and -negative patients with Alzheimer disease. However, in direct comparison of the two matched groups, the abnormalities in the ε4-positive group were demonstrated to be more pronounced.
This paper references
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
G. Mckhann (1984)
[Clinical diagnosis of Alzheimer's disease].
A. Kurz (1988)
10.1016/S0009-9260(05)80985-7
Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268
M. Torrens (1990)
Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review.
S. Rapoport (1991)
Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review.
Rapoport Si (1991)
An automated method for rotational correction and centering of three-dimensional functional brain images.
S. Minoshima (1992)
10.1016/S0001-2998(05)80118-7
The use of positron emission tomography in the clinical assessment of dementia.
J. Mazziotta (1992)
10.1176/JNP.4.4.359
J Neuropsychiatry Clin Neurosci
S. Yudofsky (1992)
10.1212/WNL.43.12.2457
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
J. Morris (1993)
10.1212/WNL.43.2.250
Vascular dementia
G. C. Román (1993)
Vascular dementia: diagnostic criteria for research studies
GC Roman (1993)
Anatomic standardization: linear scaling and nonlinear warping of functional brain images.
S. Minoshima (1994)
10.1192/BJP.167.4.533
Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease.
J. Norrman (1995)
10.1016/0304-3940(94)11107-T
Apolipoprotein ϵ4 allele and disease progression in patients with late-onset Alzheimer's disease
H. Basun (1995)
10.1212/WNL.45.7.1323
Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease
E. Corder (1995)
Apolipoprotein epsilon 4 allele and disease progression in patients with late-onset Alzheimer's disease.
H. Basun (1995)
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.
S. Minoshima (1995)
10.1056/NEJM199603213341202
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
E. Reiman (1996)
10.1212/WNL.46.3.673
Apolipoprotein E element 4 association with dementia in a population-based study
R. Myers (1996)
Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study.
R. Myers (1996)
10.1093/clinchem/43.9.1657
Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes.
A. Zivelin (1997)
Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele.
T. Arendt (1997)
Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT.
P. Bartenstein (1997)
10.1002/ANA.410420114
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
S. Minoshima (1997)
10.1006/nbdi.1997.0161
Apolipoprotein E, a Gene with Complex Biological Interactions in the Aging Brain
A. Roses (1997)
10.1001/ARCHNEUR.1997.00550150035013
No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes.
E. Corder (1997)
10.1523/JNEUROSCI.17-02-00516.1997
Plastic Neuronal Remodeling Is Impaired in Patients with Alzheimer’s Disease Carrying Apolipoprotein ε4 Allele
T. Arendt (1997)
10.1097/00002093-199812000-00018
Lack of Association of Apolipoprotein E ε4 Allele Dose with Cerebral Glucose Metabolism in Alzheimer Disease
N. Hirono (1998)
10.1016/S0304-3940(98)00673-9
Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease
R. Mielke (1998)
10.1136/jnnp.64.6.742
Longitudinal SPECT study in Alzheimer’s disease: relation to apolipoprotein E polymorphism
(1998)
Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer disease.
N. Hirono (1998)
10.1016/S0006-8993(99)01894-6
Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent
U. Beffert (1999)
18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis.
A. Drzezga (1999)
10.1007/s004010051080
Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions
T. Ohm (1999)
10.1212/WNL.53.9.2010
Metrifonate treatment of AD
M. Farlow (1999)
10.1176/JNP.11.1.66
Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease.
N. Hirono (1999)
10.1073/PNAS.090106797
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.
G. Small (2000)
10.1056/NEJM200008173430701
Patterns of brain activation in people at risk for Alzheimer's disease.
S. Bookheimer (2000)
10.1177/089198870101400110
Single Photon Emission Computed Tomography and Apolipoprotein E in Alzheimer's Disease: Impact of the ε4 Allele on Regional Cerebral Blood Flow
P. Høgh (2001)
10.1073/pnas.061509598
Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
E. Reiman (2001)
10.1073/pnas.191044198
Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)
M. D. de Leon (2001)
10.1007/s007020170066
Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype
M. Sjögren (2001)
Single photon emission computed tomography and apolipoprotein E in Alzheimer's disease: impact of the epsilon4 allele on regional cerebral blood flow.
P. Høgh (2001)
Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.
K. Ishii (2001)
10.1093/BRAIN/AWF185
Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease.
K. Bradley (2002)
10.1016/S0022-510X(02)00299-X
Functional neuroimaging in Alzheimer's type dementia
A. Demetriades (2002)
10.1016/S0006-8993(01)03367-4
Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein
B. Nathan (2002)
10.1212/WNL.58.7.1045
APOE genotype and survival in men and women with Alzheimer’s disease
G. Dal Forno (2002)
10.1136/jnnp.73.6.672
The apolipoprotein E ε2 allele and decline in episodic memory
Robert S. Wilson (2002)
Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele.
E. Mori (2002)
The apolipoprotein E epsilon 2 allele and decline in episodic memory.
R. Wilson (2002)
10.1002/ana.10093
Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E ε4 allele
E. Mori (2002)
10.1212/01.WNL.0000042478.08543.F7
Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease
D. Bennett (2003)
10.1073/pnas.2635903100
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
E. Reiman (2003)
Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.
D. Bennett (2003)
10.1007/s00259-003-1194-1
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study
A. Drzezga (2003)
10.1126/SCIENCE.300.5616.43
Still Debated, Brain Image Archives Are Catching On
M. Barinaga (2003)
Cerebral metabolic changes accompanying conversion of MCI into Alzheimer’s disease. A PET follow-up study
A Drzezga (2003)



This paper is referenced by
10.1016/j.neuron.2021.03.024
Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia
Chao Wang (2021)
10.1111/ejn.15494
Going round in circles—The Papez circuit in Alzheimer's disease
(2021)
10.1186/s13550-021-00771-0
The pons as reference region for intensity normalization in semi-quantitative analysis of brain 18FDG PET: application to metabolic changes related to ageing in conventional and digital control databases
A. Verger (2021)
10.1101/2021.03.08.21252999
Glucose metabolism reflects local atrophy and tau pathology in symptomatic Alzheimers disease
A. Strom (2021)
10.1371/journal.pone.0225392
Evidence in support of chromosomal sex influencing plasma based metabolome vs APOE genotype influencing brain metabolome profile in humanized APOE male and female mice
Yuan Shang (2020)
10.3233/JAD-200444
Single Nucleotide Polymorphisms in Alzheimer's Disease Risk Genes Are Associated with Intrinsic Connectivity in Middle Age.
Jenna Katherine Blujus (2020)
10.12688/f1000research.21599.1
Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases
Yiwei Wang (2020)
10.3389/fneur.2019.00486
Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients
Qian Zhao (2019)
10.1007/s12264-019-00340-5
Activation of the Brain to Postpone Dementia: A Concept Originating from Postmortem Human Brain Studies
Qiong-Bin Zhu (2019)
10.1016/j.nicl.2019.101795
The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study
M. Paranjpe (2019)
Quantitative 18 FAV 1451 brain tau PET imaging in cognitively normal older adults , mild cognitive impairment , and Alzheimer ' s disease patients
Qian Zhao (2019)
10.1038/s41582-019-0228-7
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yu Yamazaki (2019)
Integrating Neuroimaging and Genetics Data in a Bioinformatics-based Approach for the Study of Alzheimer’s Disease
S. Patel (2019)
10.1016/J.IFACOL.2019.02.002
Modeling Spatial and Temporal Patterns of APOE ε4 Mediated Glucose Uptake in Mild Cognitive Impairment and Normal Controls
X. Chen (2018)
DNA methylation of TOMM40-APOE locus and Alzheimer’s disease pathology in the prefrontal cortex
Natalia Ewa Bezuch (2018)
10.1016/j.neuroimage.2018.05.052
Disrupted topology of the resting state structural connectome in middle-aged APOE ε4 carriers
L. Korthauer (2018)
Structural and Functional Brain Connectivity in Middle-Aged Carriers of Risk Alleles for Alzheimer's Disease
L. Korthauer (2018)
10.1152/ajpendo.00377.2017
The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease.
Jill K. Morris (2018)
ApoE2-Mediated Neuroprotective Mechanism Through Up-regulation of Glycolysis
X. Zhang (2018)
10.3233/JAD-171047
Calpain I Activation Causes GLUT3 Proteolysis and Downregulation of O-GlcNAcylation in Alzheimer's Disease Brain.
Jianlan Gu (2018)
10.1038/s41391-018-0037-x
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
M. Cherrier (2018)
Clusterin in the Brain
Sarah K. Woody (2017)
10.1007/s00259-017-3790-5
18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer’s disease (AD) patients at the mild cognitive impairment (MCI) stage
S. Morbelli (2017)
10.1001/jamaneurol.2016.5349
Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non–Alzheimer Disease Pathophysiology
S. Schreiber (2017)
10.7912/C2RH1T
Tau and neurodegeneration : neuroimaging, genes, and biomarkers
Kacie D. Deters (2017)
10.1016/j.neurobiolaging.2016.03.033
Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
V. Garibotto (2017)
10.4103/1673-5374.221160
Mitochondrial protective and anti-apoptotic effects of Rhodiola crenulata extract on hippocampal neurons in a rat model of Alzheimer's disease
Jun-mei Wang (2017)
Revisiting the genetics of APOE
S. Carmona (2017)
10.1038/srep32573
Inter-hemispheric functional dysconnectivity mediates the association of corpus callosum degeneration with memory impairment in AD and amnestic MCI
Yin-Wei Qiu (2016)
10.3233/JAD-160395
Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.
E. Seo (2016)
10.3233/JAD-160307
Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase.
Sarah K. Woody (2016)
10.5772/64233
Clusterin (APOJ) in Alzheimer’s Disease: An Old Molecule with a New Role
Sarah K. Woody (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar